Nektar Therapeutics (NKTR) Operating Leases (2019 - 2026)

Nektar Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $60.6 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 22.76% year-over-year to $60.6 million in Q1 2026; TTM through Mar 2026 was $60.6 million, a 22.76% decrease from a year earlier, with the FY2025 full-year figure at $65.3 million, down 21.09% from the prior year.
• Operating Leases slipped to $60.6 million in Q1 2026 per NKTR's latest filing, from $65.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $122.6 million in Q1 2022 and bottomed at $60.6 million in Q1 2026.
• The 5-year median for Operating Leases is $94.7 million (2024), against an average of $93.5 million.
• Across the five-year window, Operating Leases decreased 8.86% in 2022 and decreased 22.76% in 2026, its largest moves.
• Year by year, Operating Leases stood at $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then retreated by 16.06% to $82.7 million in 2024, then declined by 21.09% to $65.3 million in 2025, then declined by 7.09% to $60.6 million in 2026.
• Per Business Quant, the three latest NKTR Operating Leases figures stand at $60.6 million (Q1 2026), $65.3 million (Q4 2025), and $69.7 million (Q3 2025).